NCT01109121

Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)

A Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety and Efficacy of Tranilast in Combination With Allopurinol in Patients With Moderate to Severe Gout (TAnGO)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 112 (actual)
• Sponsor: Nuon Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This Phase 2 study will be a multicenter, double-blind, randomized, active-comparator study to evaluate the safety and efficacy of tranilast in combination with allopurinol in patients with hyperuricemia and moderate to severe gout.

Conditions

• Moderate to Severe Gout
• Hyperuricemia

Interventions

Type	Name	Description
DRUG	Combination 400	Tranilast 300 mg QD; Allopurinol 400 mg QD
DRUG	Allopurinol	Allopurinol 400 mg, QD
DRUG	Combination 600	Tranilast, 300 mg QD; Allopurinol 600 mg QD

Timeline

• Start date: 2010-06-01
• Primary completion: 2010-12-01
• Completion: 2011-01-01
• First posted: 2010-04-22
• Last updated: 2011-01-06

Locations

24 sites across 1 country: United States